HPV Vaccine Hesitancy: Why Newcomers to Canada Face Unique Challenges
"Understanding the Barriers and Facilitators to HPV Vaccine Uptake in a Diverse Population"
Human papillomavirus (HPV) is a common sexually transmitted infection, and the HPV vaccine is a critical tool in preventing related cancers and diseases. While the vaccine is readily available in Canada, uptake rates vary, and certain groups face distinct hurdles. Newcomers, including immigrants and refugees, often encounter unique challenges when accessing healthcare services, which can significantly impact their vaccination decisions.
This article explores the experiences of healthcare providers in Ottawa, Ontario, who administer the HPV vaccine to newcomers. By examining their perspectives, we aim to understand the specific barriers and facilitators that influence HPV vaccine uptake in this population. The findings offer valuable insights into how healthcare systems and providers can better support newcomers in making informed decisions about their health.
This analysis is particularly relevant given the diverse cultural backgrounds and potential language barriers newcomers face. By addressing these factors, healthcare professionals can improve communication, build trust, and ultimately increase HPV vaccine uptake, thereby protecting the health of these vulnerable individuals.
Current Coverage and Public Health Impact
HPV vaccination is recommended to prevent new HPV infections and HPV-associated diseases, including some cancers. According to CDC National Health Interview Survey data, 38.6% of U.S. children ages 9–17 had received at least one HPV vaccine dose in 2022. Coverage differed by insurance status: 41.5% of privately insured children, 37.0% of children with Medicaid, 30.2% with other government coverage, and 20.7% without insurance had received one or more doses. The HPV Vaccination Impact Report describes ongoing efforts to identify barriers, improve vaccination coverage, and support cervical cancer elimination plans.
Routine Prevention and Its Limits
The standard approach generally combines recommended immunization with communication, follow-up, and preventive screening. In practice, this approach may be limited when people face unfamiliar health systems, language barriers, concerns about vaccine safety, or difficulty completing a multi-step care process. These limitations can make a generally effective public-health strategy less accessible, although their relative importance may differ across communities.
From Vaccine Development to Global Use
The first HPV vaccine became available in 2006, marking a major milestone in prevention against infection by selected HPV types. St. Jude Research reports that HPV vaccination has been available in the United States since 2006 and has been administered more than 270 million times globally. Current licensed products include bivalent, quadrivalent, and nonavalent vaccines, protecting against two, four, and nine HPV types respectively.
Unpacking the Barriers: What's Holding Newcomers Back?
Several factors contribute to the challenges newcomers face regarding the HPV vaccine. These barriers can be broadly categorized into access issues, communication difficulties, knowledge gaps, cultural considerations, and provider-level challenges. Understanding these specific barriers is crucial for developing effective interventions.
- Cost: The expense of the HPV vaccine series can be a significant barrier.
- Language Barriers: Communication challenges can make it difficult for providers to explain the vaccine's benefits and address concerns.
- Knowledge Gaps: Many newcomers may have limited prior knowledge of HPV and its associated risks.
- Cultural Considerations: Cultural beliefs and practices can influence attitudes towards vaccination.
- Healthcare System Navigation: Difficulties understanding how to access and utilize healthcare services can hinder vaccination efforts.
Evidence on Safety, Effectiveness, and Innovation
Recent reviews continue to report strong evidence that HPV vaccines prevent cancer and precancerous disease and provide substantial public-health benefits. A 2026 evidence review examined 121 new peer-reviewed studies published between September 2024 and January 2026, alongside 153 studies included in two major 2025 reviews. Other recent reviews discuss vaccine biology, immunogenicity, effectiveness, global disease trends, and the potential future role of therapeutic vaccines. Research on reduced-dose schedules may help inform policies intended to expand access and increase vaccination coverage.
Persistent Barriers and Uncertainty
Even when evidence supports vaccination, uptake may remain incomplete. Hesitancy can reflect concerns about safety, uncertainty about the vaccine’s purpose, limited trust, or practical barriers to accessing care. Available summaries also suggest that improving coverage requires attention to implementation and access, not only to the scientific evidence. The specific combination of barriers may vary among newcomer communities.
Unequal Access to Prevention
Comparisons of vaccination uptake should account for differences in insurance coverage, health-system access, communication, and prior experience with preventive care. A single national rate may therefore conceal meaningful differences between groups. For newcomers, the relevant comparison is not only whether vaccination is recommended, but also whether the recommendation is understandable, trusted, affordable, and practically reachable. These factors make direct comparisons difficult without population-specific evidence.
Moving Forward: Strategies to Improve HPV Vaccine Uptake
Addressing the unique challenges newcomers face requires a multifaceted approach. Enhancing communication through culturally sensitive resources, providing clear and accessible information, and fostering trust between healthcare providers and newcomers are crucial steps. Public health initiatives, tailored to meet the needs of diverse communities, can play a vital role in improving HPV vaccine uptake and protecting the health of all residents.
Evidence and Trust Must Work Together
The available evidence supports HPV vaccination as an important cancer-prevention intervention, but evidence alone may not resolve hesitancy. Effective communication must connect the vaccine’s preventive purpose with people’s questions, expectations, and experiences of the health system. For newcomers, building trust and making care easier to navigate may be as important to uptake as repeating general recommendations. The strongest response is therefore likely to combine sound clinical evidence with culturally and practically responsive delivery.
Expanding Access and Improving Delivery
Future work is likely to focus on increasing vaccination coverage while preserving confidence in safety and effectiveness. Reduced-dose schedules are being studied as a possible way to expand access and inform future policy. Reviews also identify combined prevention approaches involving vaccination, early detection, and personalized treatment. Progress will depend on translating these developments into services that people can understand and complete.
Health Systems Shape Vaccine Uptake
HPV vaccine hesitancy is shaped not only by individual beliefs but also by the systems through which people receive information and care. Insurance differences, language access, unfamiliar procedures, and fragmented services can all make prevention harder to obtain. Newcomers may encounter several of these challenges at once. Addressing them requires health-system responses that reduce practical barriers alongside respectful, clear communication.
From Clinical Evidence to Everyday Protection
Real-world studies are important because they show how HPV vaccines perform in clinical and public-health practice, beyond controlled trial settings. Researchers have assessed vaccine effectiveness by age at vaccination, while registry-based studies initially examined outcomes such as genital warts and cervical precancer because cancer can develop long after causal HPV infection. A 2025 report also described research evaluating herd immunity in real-world settings that included young women at relatively high risk for HPV and different levels of vaccination. These findings highlight that vaccination can affect both vaccinated individuals and, through population protection, some people who remain unvaccinated.